Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2013. The report details a specific share repurchase transaction executed on September 13, 2013, authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,235,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,626.00 pence; lowest price paid was 1,615.50 pence.
- Treasury Holdings (Settled): 517,760,412 shares (9.56% of total issued share capital).
- Treasury Holdings (Including Unsettled): 521,407,412 shares (10.65% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,896,337,904 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,235,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.65% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (517,760,412 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (10.65% held in Treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (4,896,337,904 shares in issue).
- Review the price paid per share (1,615.50 to 1,626.00 pence) against market prices on September 13, 2013.